WWW.PHARMAORG.COM WWW.PHARMAORG.COM: Any drug you wish to know about


SYNALAR CREAM       

      Synalar Cream is used to reduce itching, redness, and swelling associated with many skin conditions.

How Taken
Apply a small amount of medicine to the affected area. Gently rub the medicine in until it is evenly distributed. Wash your hands after applying this medicine, unless your hands are part of treated area. Do not bandage or wrap the affected area unless directed otherwise by your doctor.

Warnings/Precautions
If your condition shows no signs of improvement or becomes worse within a few days, check with your doctor. Avoid contact with the eyes. Do not use Synalar Cream longer than the time prescribed. Tell your doctor if you are breast-feeding before taking this medicine.

Missed Dose
If you miss a dose, apply it as soon as you remember. If it is near the time of the next application, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.

Possible Side Effects
Some of the side effects you may experience include: skin thinning and discoloration, itching, burning, redness, or swelling not present before using this medicine.

Searching for something else? No problem!

Search for anything:

Implanted Nerve Stimulator Eases Epilepsy in Kids.
         Stimulation of a cranial nerve through an implant can effectively treat some children with epilepsy, according to the results of a new two-year study. In a study of more than 75 young patients, doctors found that 59 percent of those implanted with a vagus nerve stimulator did not suffer from localization-related epilepsy, or seizures occurring in one part of the brain. Hospital visits for epilepsy-related conditions also decreased by 41 percent, the researchers reported Wednesday at the International League Against Epilepsy Congress in Paris. The nerve stimulator is implanted in the left side of a patient's neck and works by sending signals to the brain to decrease the electrical activity that leads to seizures. It was approved by the U.S. Food and Drug Administration in 1997 for the treatment of epilepsy unresponsive to medication.
Main Page  Site Map